Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

e 1 l E t Eliem Therapeutics, Inc. (NASDAQ:ELYM) is gearing up to report additional results from its phase 1b study using TNT119 for the treatment of patients with membranous nephropathy [MN]. It already released some prior data from this study, and now it is going to release additional results by the end of 2024, which could possibly unlock further shareholder value. The truth is that this anti-CD19 monoclonal antibody can be applied towards other autoimmune disorders because its ability to deplete a broad ...